Myeloma Survival Unchanged With Longer Lenalidomide
ENDURANCE found no seven-year survival benefit from indefinite lenalidomide maintenance, supporting fixed two-year therapy as an evidence-based option for selected standard-risk patients.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.